Evidence map›Paper›PMID 40498387›Full record

ArticleDermatology and therapy2025

Oral Supplementation with a New Hyaluronic Acid Matrix Ingredient Improves Skin Brightness, Hydration, Smoothness, and Roughness: Results from a Randomized, Double-Blinded, Placebo-Controlled Study.

Trinidad Montero-Vilchez, Patricia Gálvez-Martín, Raquel Sanabria-de la Torre, Carlos Cuenca-Barrales, Alejandro Molina-Leyva, Daniel Martinez-Puig, Javier Velasco-Alvarez, Salvador Arias-Santiago

Registry-linked trialAbstract read
In one paragraph

Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05813054 (Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05813054 nacompletednot on this map

Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®

TypeinterventionalSponsorBioibericaRan2022 to 2023Enrolled60ConditionsSkin AgingArmsHA matrix ingredient, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Trinidad Montero-VilchezDermatology Department, Hospital Universitario Virgen de Las Nieves, Instituto de Investigación Biosanitario Ibs. GRANADA, 18014, Granada, Spain.
Patricia Gálvez-MartínR&D Department, Bioibérica S.A.U., 08389, Palafolls, Spain. pgalvez@bioiberica.com.ORCID http://orcid.org/0000-0001-9724-8560
Raquel Sanabria-de la TorreDermatology Department, Hospital Universitario Virgen de Las Nieves, Instituto de Investigación Biosanitario Ibs. GRANADA, 18014, Granada, Spain.
Carlos Cuenca-BarralesDermatology Department, Hospital Universitario Virgen de Las Nieves, Instituto de Investigación Biosanitario Ibs. GRANADA, 18014, Granada, Spain.
Alejandro Molina-LeyvaDermatology Department, Hospital Universitario Virgen de Las Nieves, Instituto de Investigación Biosanitario Ibs. GRANADA, 18014, Granada, Spain.
Daniel Martinez-PuigR&D Department, Bioibérica S.A.U., 08389, Palafolls, Spain.
Javier Velasco-AlvarezR&D Department, Bioibérica S.A.U., 08389, Palafolls, Spain.
Salvador Arias-SantiagoDermatology Department, Hospital Universitario Virgen de Las Nieves, Instituto de Investigación Biosanitario Ibs. GRANADA, 18014, Granada, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe skin aging process is mainly associated with the appearance of fine wrinkles and flaccid, dry, and dull skin. A hyaluronic acid matrix (HAm) ingredient containing HA, sulfated glycosaminoglycans (GAGs), and collagen is proposed to enhance skin health by improving hydration and structural integrity. The objective of this study was to evaluate the impact of oral supplementation with HAm on skin properties.

methodsA 12-week, randomized, double-blind, placebo-controlled trial was designed, including 60 healthy women aged 35-65 with signs of natural skin aging (NCT05813054). Participants were assigned to receive either HAm (Dermial

resultsAssessments were performed on data from 50 participants as a per-protocol analysis. Skin wrinkles and smoothness (6 weeks), and roughness (12 weeks) significantly improved in the HAm group compared with the placebo group. Participants receiving HAm had significantly increased skin SCH and brightness, and decreased scaliness and temperature at 6 and 12 weeks versus the baseline value. A statistically significant reduction in the erythema index and a balanced pH were also observed in the HAm group. Global satisfaction was significantly higher in HAm as compared to placebo. No serious adverse events associated with the tested products were registered during the study.

conclusionsDaily supplementation with HAm effectively improves multiple aspects of skin health and appearance, suggesting its potential as a safe and beneficial antiaging ingredient. These results support the role of HAm in promoting skin brightness/glow and hydration, and reducing the visible effects of aging.

trial registrationClinicalTrials. gov identifier, NCT05813054.

Indexed as

AntiagingBrightnessCollagenGlowGlycosaminoglycansHyaluronic acidNutricosmeticSkinWrinkles

Identifiers

PMID40498387
PMCPMC12256382

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.